Is It Ozempic-Related Gastroparesis? Key Facts for Identification

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

If you're experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may wonder if it's gastroparesis. Decades of pharmacovigilance have established that GLP-1 agonists can slow gastric emptying, a well-documented effect. This page clarifies the distinguishing features, typical onset timeline, and diagnostic steps for Ozempic-associated gastroparesis.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-related increase in gastrointestinal symptoms that may mimic or exacerbate gastroparesis.

The Link Between Ozempic and Gastroparesis

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse effects reported with Ozempic, including nausea, vomiting, dyspepsia, and gastroesophageal reflux disease. In clinical trials, dyspepsia occurred in 1.9% of placebo patients, 3.5% of those on Ozempic 0.5 mg, and 2.7% on Ozempic 1 mg; gastroesophageal reflux disease occurred in 0%, 1.9%, and 1.5% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors, which slow gastric emptying. GLP-1 receptor agonists like semaglutide delay gastric emptying as part of their therapeutic effect on postprandial glucose control. However, this pharmacodynamic effect can become pathological in susceptible individuals, leading to clinically significant gastroparesis. The reported adverse reactions of nausea, vomiting, and dyspepsia are consistent with delayed gastric emptying. While the prescribing information does not explicitly list gastroparesis as a labeled adverse reaction, the gastrointestinal effects are well-documented and include conditions such as gastritis, which occurred in 0.8% of placebo, 0.8% of Ozempic 0.5 mg, and 0.4% of Ozempic 1 mg patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific warning for gastroparesis raises questions about the adequacy of warnings regarding this potential harm.

Legal Implications and Lawsuit Settlement Criteria

From a risk perspective, the adequacy of warnings is a central issue. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no explicit warning about the risk of gastroparesis. This omission may be significant for patients who develop severe gastrointestinal symptoms that persist beyond dose escalation. The timeline between exposure and documented harm is critical: gastrointestinal adverse reactions are most common during dose escalation, but some patients may experience prolonged symptoms that meet diagnostic criteria for gastroparesis. The lack of a specific warning could delay diagnosis and treatment, potentially leading to complications such as malnutrition, dehydration, and poor glycemic control. For affected patients, attorney-related considerations include the need to establish a causal link between Ozempic use and the development of gastroparesis. This requires documentation of the timeline of exposure, symptom onset, and diagnostic confirmation through gastric emptying studies. The clinical trial data show a clear dose-response relationship for gastrointestinal adverse reactions, which may support causation. Additionally, the absence of a specific warning in the prescribing information could be relevant in litigation, as it may indicate that the manufacturer failed to adequately communicate the risk. Patients should consult with a healthcare provider to document their symptoms and consider whether Ozempic is the likely cause. Legal counsel can help evaluate whether the case meets criteria for a lawsuit, including the severity of harm, the timing of symptoms relative to drug initiation, and the adequacy of warnings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to symptoms consistent with gastroparesis, such as nausea, vomiting, and bloating. Clinical trials show a dose-related increase in gastrointestinal adverse reactions, including dyspepsia and gastroesophageal reflux disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as a side effect, the overlapping symptoms and mechanistic plausibility support a potential association.

What are the criteria for an Ozempic gastroparesis lawsuit?

Key criteria include documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying study, symptom onset after starting Ozempic, and evidence that the manufacturer failed to adequately warn about the risk. The absence of a specific gastroparesis warning in the prescribing information may be a central issue. Patients should consult an attorney to evaluate their case based on severity of harm, timing, and adequacy of warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.